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A CD4+ cytotoxic T-lymphocyte (CTL) clone, established from the peripheral blood of a human immuno-
deficiency virus (HIV)-seropositive donor, lysed autologous target cells that were infected with a recombinant
vaccinia virus containing the gag gene of HIV type i and target cells pulsed with p249aB construct expressed
in Escherichia coli. The recognition of the HLA-DQ-restricted epitope by this clone was further defined by
using overlapping synthetic peptides. The epitope recognized by this CD4+ CTL clone (amino acids 140 to 148)
overlaps with a CD8+ epitope and is highly conserved among all isolates of HIV type 1 that have been
sequenced. Production and secretion of lymphokines such as interleukin-2 and interleukin-6 after specific
antigenic stimulation were demonstrated by this gag-specific CD4+ CTL clone.
Virus-specific cytotoxic T lymphocytes (CTL) are gener-
ally considered to recognize viral antigens presented by class
I major histocompatibility complex (MHC) molecules, but a
number of studies have described CD4+ CTL restricted by
class II MHC alleles which are specific for target cells
exposed to exogenous viral proteins. Several reports have
described CD8+ class I-restricted CTL in the peripheral
blood lymphocytes of individuals with human immunodefi-
ciency virus type 1 (HIV-1) infection (19); however, there
have been no reports about viral antigens involved in HIV-
specific class II-restricted CTL recognition. Although they
were isolated in the cerebrospinal fluid (15), CD4+ cytotoxic
T cells in the peripheral blood lymphocytes of HIV-1 in-
fected individuals have not been described. The only report
of HIV-1-specific CD4' CTL in peripheral blood lympho-
cytes was in healthy, seronegative individuals following
immunization with a recombinant HIV-1 gp160 subunit
vaccine (11). Since class II-restricted CTL may form an
important component of the immune response to HIV-1, it is
important to define HIV viral epitopes that are presented by
class II MHC molecules.
We previously reported a CD8+ HIV-1 gag-specific cyto-
toxic T-cell clone which is restricted by a class I molecule,
HLA-Cw3 (7). An epitope on p24, with the sequence
QAISPR (amino acids [aa] 145 to 150), which is highly
conserved among all of the HIV-1 isolates that have been
sequenced, was recognized by this clone. We subsequently
isolated a CD4+ T-cell clone, designated 108.2, which rec-
ognized a region of p24 (aa 140 to 148) that overlaps with this
CD8+ epitope. This CD4+ CTL clone secretes high levels of
interleukin-2 (IL-2) and IL-6 but not IL-4 upon activation.
This region of p249a^' is highly conserved on different HIV-1
isolates and it is capable of inducing both CD8+ and CD4+
CTL responses. Thus, this region of p24 may be of interest
for purposes of HIV-1 peptide-based vaccine development.
Determination of CTL epitope on p24Kag. The preparation
of target and effector cells for cytotoxicity assays and
* Corresponding author.
phenotypic analysis has been described previously (7). We
had observed that this donor's peripheral blood mononu-
clear cells showed significant HIV-1 gag, pol, and envelope-
specific killer cell activity in bulk culture experiments (7).
After subcloning by limiting dilution, a CD3+ CD4+ CD8-
CD16- CTL clone, 108.2, was isolated from a well seeded
with 0.3 cell per well. This clone lysed vaccinia virus
(VAC)/gag- but not VAC-, VAC/pol-, or VAC/env-infected
target cells (data not shown). To localize the epitope on gag,
we added recombinant p24 antigen to autologous B-LCL
target cells in a cytotoxicity assay. As shown in Fig. 1, these
target cells were lysed to a level similar to that of VAC/gag-
infected targets. Lysis of K562 cells and VAC-infected or
uninfected B-LCL cells was minimal.
To identify the epitope on p24 which induced this CTL
response, we synthesized a series of 14 overlapping peptides
derived from the p24 amino acid sequence of the human
T-cell lymphotropic virus IIIB isolate. As seen in Table 1
(experiment A), convincing cytotoxic activity was observed
only on target cells pulsed with peptide 2 (amino acid
residues 143 to 172). Peptide 1, which overlaps peptide 2 by
20 amino acids, did not sensitize target cells for lysis.
A series of smaller peptides contained in the amino acid
sequence of peptide 2 were synthesized in order to define the
core epitope recognized by this CD4+ CTL clone (Table 1,
experiment B). Target cells pulsed with peptide 90-17, which
corresponds to amino acid residues 133 to 152, were lysed by
this CTL clone. The removal of 13 amino acids from the N
terminus (peptide 90-17A) abrogated all activity, while re-
moval of 5 or 7 amino acid residues at the N-terminal side of
the sequence (peptides 90-17B and 90-17C, respectively) did
not change the specific lysis of target cells. In addition, the
removal of four amino acid residues (149 to 152) at the C
terminus (peptides 90-18, 90-18A, and 90-18B) did not alter
recognition by the clone. Therefore, the epitope recognized
by this CD4+ CTL clone lies within residues 140 to 148
(GQMVHQAIS) of the p24 region of gag. The sequence of
this epitope is highly conserved among all of the 18 North
American or European strains sequenced to date, although
there is a conservative amino acid substitution at position
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FIG. 1. Specificity of clone 108.2 for HIV-1 p24 protein. The
CTL clone was tested for specific lysis of autologous B-LCL cells
that were uninfected or expressing wild-type VAC, recombinant gag
(VAC/gag), or p24 protein. K562 cells were used as another target
cell. The CTL assay was performed in triplicate at an effector/target
ratio of 2.5:1.
143 (isoleucine for valine) and residue 146 (proline for
alanine) in the African isolates HIV-1 MAL and OYI,
respectively.
We previously demonstrated that this region of p24 con-
tains a class I HLA-Cw3-restricted epitope (7). Our results
confirm previous observations that similar peptides can be
recognized in a class I- and class II-restricted manner. Other
investigators have described an overall similarity for struc-
tures of class I and class II MHC molecules (2, 5). The use
of similar T-cell receptors by class I- and class II-restricted
T cells (8, 14) suggests that antigen recognition mechanisms
are similar in the two systems. Perkins et al. (12) reported
that seven individual influenza virus peptides were able to
stimulate both class I- and class II-restricted T-cell re-
sponses. Recently, Takahashi et al. observed that different
sites located on the V3 loop of the HIV-1 env protein
stimulated class I H-2d-restricted CD8+ CTL and induced
T-cell help for itself (17). Our results indicate that the epitope
which we previously defined as a class I-restricted epitope
on p249ag overlaps with this class II-restricted response.
Thus, this region (aa 140 to 150) of p24 may be a candidate
for inclusion in an AIDS subunit vaccine.
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FIG. 2. MHC restriction of clone 108.2. Autologous and alloge-
neic targets matched at one or more HLA loci as indicated were
infected with VAC/gag (A) or pulsed for 1 h with peptide 90-18B (B).
Percent specific lysis was determined at an effector/target ratio of
3:1. The HLA class II alleles of the donor are DQw1, DQw3, DR4,
DR10, and DRw53.
HLA restriction of cytolysis by CTL clone 108.2. The CD4+
gag-specific clone was tested for its cytolytic activity by
using as target cells allogeneic B-LCL cells infected with
VAC/gag matched at one or more HLA class II loci or
unmatched as indicated in Fig. 2. The HLA class II alleles of
the donor of clone 108.2 are DR4, DR10, DQwl, DQw3, and
DRw53. We observed lysis of allogeneic target cells that
shared DQw1 or DQw3 (Fig. 2A). This observation was
confirmed in another experiment (Fig. 2B) by using other
allogeneic targets pulsed with the core peptide, which also
demonstrated recognition of the peptide in association with
DQwl or DQw3. In addition, we observed the inability of
this CTL clone to lyse two HLA-matched allogeneic targets
sharing DQwl or DQw3 although it successfully lysed other
allogeneic targets with DQwl and DQw3 in the same assay.
There is a high degree of structural homology among DQ
TABLE 1. Lysis of peptide-pulsed target cells by CD4+ clone 108.2
Expt Peptide no. Residues" Amino acid sequence % Specificlysisb
A 1 133-162 1.9
2 143-172 25.6
3 153-182 5.1
4 173-202 1.7
5-14 193-363 0
B 2 143-172 18.5
90-17 133-152 PIVQNIQGQMVHQAISPRTL 15.1
90-17A 146-152 AISPRTL -3.4
90-17B 138-152 IQGQMVHQAISPRTL 16.6
90-17C 140-152 GQMVHQAISPRTL 20.1
90-18 133-148 PIVQNIQGQMVHQAIS 14.3
90-18A 138-148 IQGQMVHQAIS 14.7
90-18B 140-148 GQMVHQAIS 16.8
"Residue numbering for the p24TM'1 sequence is based on the HIV-1 (IIIB strain) sequence.b Autologous B-LCL cells were pulsed with peptides at a final concentration of 50 p.g/ml for 1 h before being labeled with 5"Cr and used as targets for clone
108.2. Percent specific lysis was determined at an effector/target ratio of 3:1.
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TABLE 2. Lymphokine production" by CD4+ CTL clone 108.2 in response to purified p24 protein, peptide antigen, and 12F6
Stimulantb IL-2 (pg/ml)' IL-6 (pg/ml) IL-4 (ng/ml)' IFN--y (pg/ml) TNF-a (pg/ml)
p24 protein 720 1,650 ND 2,588 176
Peptide 1 (aa 140-152) 700 1,963 ND 3,294 238
90-18B (aa 140-148) 754 1,438 ND 2,711 241
90-25 (aa 141-152) 660 1,422 ND 3,671 241
12F6d 390 3,390 ND 7,376 662
Peptide 14 (aa 334-363) 44 514 ND 2,555 204
None 22 404 ND 3,120 275
a Supernatants were harvested 3 days after the onset of the stimulation.
b The autologous B-LCL cells used as antigen-presenting cells, after 8 h of incubation with different peptides or overnight pulsing with p24 protein at
concentrations of 100 pug/ml, had been irradiated with 5,000 rad.
c IL-4 levels of <0.022 ng/ml were not detected (ND).
d Anti-CD3 MAb, used at a final dilution of 0.1 ptg/ml.
alleles (9). Therefore, this CTL clone probably recognizes
this epitope on a conserved site on DQw1 and DQw3 which
is present on most cells which serologically type as DQwl or
DQw3. From the known frequencies of DQ alleles in dif-
ferent individuals (1), we would expect that 55% of Cauca-
sian, 63% of African, and 67% of Asian individuals would be
capable of presenting this CD4+ epitope (aa 140 to 148)
contained in HIV-1 p24A"9.
Lymphokine production by this CD4+ CTL clone. T cells,
after antigenic stimulation, secrete lymphokines that are
major determinants of the function of lymphocytes. To
better define its biologic properties, in addition to cytotoxic
function, this CD4+ clone was examined for lymphokine
production after stimulation with purified p24 protein, the
appropriate peptide antigen, or an anti-CD3 monoclonal
antibody (MAb), 12F6. Irradiated (5,000 rads) autologous
B-LCL cells were incubated with different peptide antigens
at a concentration of 100 jig/ml for 8 h at 37°C or pulsed
overnight with 100 ,ug of purified recombinant p24 protein
per ml, then washed twice, resuspended in RPMI containing
10% fetal calf serum, and added to individual wells of
microtiter plates (100 p.l per well) containing 3 x 104 cells.
The T-cell clone was then added (4 x 104 per well) at 100 ,ul
per well. After 3 days of incubation at 37°C, 0.1 ml of
supernatant fluid was collected from each well and stored at
-70°C. Supernatants were tested for the presence of IL-2,
IL-6, tumor necrosis factor alpha (TNF-ot), IL-4, and gamma
interferon (IFN--y) activity by using commercially available
enzyme-linked immunosorbent assay kits (Biokine IL-2,
IL-6, and TNF test kits from T Cell Sciences, Cambridge,
Mass.; Intertest-4 and Intertest--y from Genzyme Corpora-
tion, Boston, Mass.). Table 2 shows that the clone produced
large amounts of IL-2 and IL-6 but no IL-4 in response to
stimulation by purified p24 protein or peptides which con-
tained the epitope (peptides 1, 90-18B, and 90-25), or the
anti-CD3 MAb 12F6. Stimulation with the p24 protein or
peptide resulted in higher production of IL-2 than did
stimulation with the anti-CD3 MAb, while the reverse was
true in terms of IL-6 secretion. This contrasts with the low
levels of IL-2 and IL-6 detected in the absence of a stimu-
latory signal. The culture supernatant from all wells includ-
ing those containing an irrelevant peptide yielded high levels
of IFN--y and TNF-a. However, stimulation with 12F6
resulted in a twofold increase in the secretion of these
lymphokines. This clone, therefore, cannot be readily clas-
sified as either a Th-1 or Th-2 type of clone as described for
the murine system, in which activated T-helper (Th-1) clones
secrete IL-2, IFN--y, and lymphotoxin, whereas Th-2 clones
secrete IL-4, IL-5, IL-6, and IL-10 (16). IL-6 is known to
induce B-cell differentiation and antibody production, and it
has also been reported to activate and enhance CTL re-
sponses of CD8+ cells that are able to secrete IL-2 (18). The
role of IL-6 in T-cell activation stems from its ability to
activate cells from Go to an early stage in G1 in which they
become blastic and express IL-2 receptors. This leads to
increased IL-2 responsiveness which further moves the cells
towards the S phase, causing proliferation of these T cells.
This induction of IL-2 receptors has been observed with
human T cells through the synergistic actions of IL-6 and
IL-2 (18).
The biological role of CD4+ CTL in HIV-1-infected indi-
viduals is not known. It is reasonable to assume that CD4+
CTL responses are induced by HIV-1-infected cells which
express relatively large amounts of MHC class II antigens,
such as macrophages, B cells, and activated T cells, whereas
resting CD4+ T cells, which express mainly MHC class I
antigens, would induce CD8+ but not CD4+ CTL responses.
CD4+ CTL responses have been reported for other viral
systems, such as measles virus (3), herpes simplex virus
(20), dengue virus (6), and influenza virus (4); therefore,
CD4+ CTLs may play a role in vivo by killing virus-infected
MHC class II-bearing target cells. The relative lack of
detection of HIV-1-specific CD4+ CTL compared with
CD8+ CTL may be due in part to the lower level of lysis in
vitro generally caused by CD4+ CTL or to methods we and
others use for detecting HIV-1 virus-specific CTL (7, 19).
The level of lysis by CD4+ and CD8+ CTL is variable.
Dengue virus CD4+ CTL clones (6) varied in their level
of lytic activity, and some CD4+ clones had a moderate level
of lysis similar to that caused by this HIV-1 CD4+ CTL
clone. Our results suggest that CD4+ CTL are part of the
effector population in HIV-infected individuals, by virtue of
their cytotoxic activity and lymphokine secretion. These
CTL may also contribute to the immunodeficient state by
killing infected cells. It is critically important to determine
the reasons why such CTL responses are unable to com-
pletely eliminate infected cells in individuals infected with
HIV-1 or other lentiviruses, unlike with other virus infec-
tions (10, 13).
We thank B. Moss for recombinant vaccinia viruses expressing
HIV-1 genes, J. Wong for the anti-CD3 MAb 12F6, C. Debouck for
the purified recombinant p24 protein, Anita Leporati for preparing
the recombinant vaccinia virus stocks, and Jurand Janus for per-
forming the lymphokine assays.
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